ScreenerHero

XBRANE Xbrane Biopharma AB (publ)

STO · SE · Healthcare · Biotechnology · xbrane.com
14.20SEK+13.60%Mkt Cap: 27.99M $P/E: —

Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
INSM
Insmed Incorporated
$22.98BUSD
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap27.99M USD
Enterprise Value21.86M USD
Revenue (TTM)7.97M USD
Gross Profit8.57M USD
Net Income (TTM)12.17M USD
Revenue/Share4.04 SEK
Last Price14.20 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees29
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0007789409
Valuation
P/E (Trailing)—
P/E (Forward)520.00
PEG—
EV/EBITDA-3.73
EV/Revenue2.74
P/S2.57
P/B0.40
EPS (TTM)-3.73
EPS (Forward)0.02
52W Range
5.42130% of range35.05
52W High35.05 SEK
52W Low5.421 SEK
Profitability
Gross Margin58.76%
Oper. Margin-5.99%
EBITDA Margin-73.64%
Profit Margin83.49%
ROE22.70%
ROA18.95%
Growth
Revenue Growth17.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.98M USD
CapEx (TTM)13.36M USD
FCF Margin-229.42%
FCF Yield-65.31%
Net Debt1.36M USD
Net Debt/EBITDA-0.23
Balance Sheet
Debt/Equity0.10
Current Ratio3.19
Quick Ratio0.71
Book Value/Sh26.15 SEK
Cash/Share2.40 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 SEK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:125
Split DateOct 17, 2025
Analyst Consensus
Rating—
Target (Mean)15.00 SEK
Upside (mean)+5.6%
Target Range15.00 SEK – 15.00 SEK
# Analysts1
Ownership
Shares Out.20.61M
Float17.35M
Insiders39.62%
Institutions9.28%
Technical
SMA 5010.08 (+40.8%)
SMA 2009.664 (+46.9%)
Beta0.85
S&P 52W Chg14.58%
Avg Vol (30d)35.30K
Avg Vol (10d)20.69K
Technical Indicators
RSI (14)77.9
MACD0.5566
MACD Signal0.2631
MACD Hist.+0.2934
BB Upper12.69 SEK
BB Middle10.76 SEK
BB Lower8.838 SEK
BB Width35.75%
ATR (14)0.6950 SEK
Vol Ratio (20d)7.97x